{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:33:46Z","timestamp":1791999226463,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10157-021-02090-z","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T09:03:12Z","timestamp":1623402192000},"page":"1193-1202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience"],"prefix":"10.1007","volume":"25","author":[{"given":"Masatoyo","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Komatsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"2090_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak AZ. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9\u201322.","journal-title":"FASEB J"},{"key":"2090_CR2","doi-asserted-by":"publisher","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","volume":"280","author":"N Ferrara","year":"2001","unstructured":"Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280:C1358-1366.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2090_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VFGF signaling a d associated nephrotoxicities. J Am Soc Nephrol. 2019;30:187\u2013200.","journal-title":"J Am Soc Nephrol"},{"key":"2090_CR4","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"2090_CR5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Ned. 2008;358:1129\u201336.","journal-title":"N Engl J Ned"},{"key":"2090_CR6","first-page":"267","volume":"70","author":"ESG den Deurwaarder","year":"2012","unstructured":"den Deurwaarder ESG, Desar IME, Steenbergen EJ, Mulders PF, Wetzels JFM, van Herpen CML. Kidney injury during VEGF inhibitor therapy. Neth J Med. 2012;70:267\u201371.","journal-title":"Neth J Med"},{"key":"2090_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gft465","volume":"29","author":"C Vigneau","year":"2014","unstructured":"Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, et al. All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a RARe study. Nephrol Dial Transplant. 2014;29:325\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"2090_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth f actor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93:333\u20139.","journal-title":"Medicine (Baltimore)"},{"key":"2090_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, B\u00fcttner A, B\u00fcttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73:990\u20131001.","journal-title":"Histopathology"},{"key":"2090_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32:684\u2013700.","journal-title":"Mod Pathol"},{"key":"2090_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s10157-016-1271-y","volume":"21","author":"M Ozawa","year":"2017","unstructured":"Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, et al. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. Clin Exp Nephrol. 2017;21:212\u201327.","journal-title":"Clin Exp Nephrol"},{"key":"2090_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10157-020-01859-y","volume":"24","author":"A Saito","year":"2020","unstructured":"Saito A, Komatsuda A, Saito M, Kaga H, Abe F, Sawamura M, et al. Clinicopathological features and outcomes of diabetic kidney disease with extracapillary hyper cellularity: a Japanese single-center experience. Clin Exp Nephrol. 2020;24:509\u201317.","journal-title":"Clin Exp Nephrol"},{"key":"2090_CR13","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.ekir.2018.07.008","volume":"3","author":"SH Nasr","year":"2018","unstructured":"Nasr SH, Fidler ME, Said SM. Paraffin immunofluorescence: a valuable ancillary technique in renal pathology. Kidney Int Rep. 2018;3:1260\u20136.","journal-title":"Kidney Int Rep"},{"key":"2090_CR14","doi-asserted-by":"publisher","first-page":"176973","DOI":"10.1155\/2011\/176973","volume":"2011","author":"J M\u00fcller-Deile","year":"2011","unstructured":"M\u00fcller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. J Pregnancy. 2011;2011:176973.","journal-title":"J Pregnancy"},{"key":"2090_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1756-0500-6-450","volume":"6","author":"M Yahata","year":"2013","unstructured":"Yahata M, Nakaya I, Sakuma T, Sato H, Aoki S, Soma J. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. BMC Res Notes. 2013;6:450.","journal-title":"BMC Res Notes"},{"key":"2090_CR16","first-page":"612","volume":"56","author":"M Tomita","year":"2014","unstructured":"Tomita M, Ochiai M, Shu S, Yamauchi Y, Shihara H, Ogata A, et al. A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab. Nihon Jinzo Gakkai Shi. 2014;56:612\u20137 (in Japanese with English abstract).","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"2090_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13730-020-00504-7","volume":"10","author":"M Morimoto","year":"2021","unstructured":"Morimoto M, Arai T, Matsuura M, Ono Y. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer. CEN Case Rep. 2021;10:6\u201311.","journal-title":"CEN Case Rep"},{"key":"2090_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000437253","volume":"60","author":"O Abdel-Rahman","year":"2014","unstructured":"Abdel-Rahman O, ElHalawani H. Proteinuria in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. Chemotherapy. 2014;60:325\u201333.","journal-title":"Chemotherapy"},{"key":"2090_CR19","doi-asserted-by":"publisher","first-page":"579603","DOI":"10.3389\/fmed.2020.579603","volume":"7","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Tran NT, Patel SS, Hou J, Jhaveri KD, Parikh R, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med (Lausanne). 2020;7:579603.","journal-title":"Front Med (Lausanne)"},{"key":"2090_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","volume":"20","author":"R Yamada","year":"2019","unstructured":"Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019;20:14.","journal-title":"BMC Nephrol"},{"key":"2090_CR21","doi-asserted-by":"publisher","first-page":"e16236","DOI":"10.1097\/MD.0000000000016236","volume":"98","author":"T Fujii","year":"2019","unstructured":"Fujii T, Kawasoe K, Tonooka A, Ohta A, Nitta K. Nephrotic syndrome associated with ramucirumab therapy: a single-center case series and literature review. Medicine (Baltimore). 2019;98:e16236.","journal-title":"Medicine (Baltimore)"},{"key":"2090_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13730-020-00474-w","volume":"9","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Uehara A, Suzuki T, Sekine R, Yazawa M, Ichikawa D, et al. Nintedanib-induced glomerular microangiopathy: a case report. CEN Case Rep. 2020;9:295\u2013300.","journal-title":"CEN Case Rep"},{"key":"2090_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/ki.2011.497","volume":"81","author":"D Cohen","year":"2012","unstructured":"Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V, et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012;81:628\u201339.","journal-title":"Kidney Int"},{"key":"2090_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jcp.2005.035592","volume":"60","author":"KO Alsaad","year":"2007","unstructured":"Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007;60:18\u201326.","journal-title":"J Clin Pathol"},{"key":"2090_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2013","unstructured":"Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2013;85:457\u201370.","journal-title":"Kidney Int"},{"key":"2090_CR26","doi-asserted-by":"publisher","first-page":"F422","DOI":"10.1152\/ajprenal.00448.2005","volume":"291","author":"F Guan","year":"2006","unstructured":"Guan F, Villegas G, Teichman J, Mundel P, Tufro A. Autocrine VEGF-A system in podocytes regulated podocin and its interaction with CD2AP. Am J Physiol Renal Physiol. 2006;291:F422\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2090_CR27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1681\/ASN.2010030295","volume":"21","author":"K Sison","year":"2010","unstructured":"Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, et al. Glomerular structure and function require paracrine, not Autocrine, VEGF\u2013VEGFR-2 signaling. J Am Soc Nephrol. 2010;21:1691\u2013701.","journal-title":"J Am Soc Nephrol"},{"key":"2090_CR28","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41598-020-58994-5","volume":"10","author":"Y Kanbayashi","year":"2020","unstructured":"Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E, et al. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis. Sci Rep. 2020;10:2011.","journal-title":"Sci Rep"},{"key":"2090_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10157-020-01957-x","volume":"25","author":"K Okada","year":"2021","unstructured":"Okada K, Usui K, Kikuchi D, Takahashi M, Watanabe Y. The risk of nephrotic syndrome with non-VEGF inhibitory antineoplastic drugs; from viewpoint of the adverse event reports in Japan. Clin Exp Nephrol. 2021;25:97\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2090_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/jjco\/hyv035","volume":"45","author":"Y Kitai","year":"2015","unstructured":"Kitai Y, Matsubara T, Yanagita M. Onco-nephrology: current concepts and future perspectives. Jpn J Clin Oncol. 2015;45:617\u201328.","journal-title":"Jpn J Clin Oncol"},{"key":"2090_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3322\/caac.21636","volume":"71","author":"MH Rosner","year":"2021","unstructured":"Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin. 2021;71:47\u201377.","journal-title":"CA Cancer J Clin"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-021-02090-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T14:17:30Z","timestamp":1632406650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-021-02090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1007\/s10157-021-02090-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Naoto Takahashi has received grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Pfizer, grants and personal fees from Otsuka Pharmaceutical, grants from Kyowa Kirin, grants from Astellas Pharma, grants from Chugai Pharmaceutical, grants from Asahi Kasei Pharma, grants from Ono Pharmaceutical, and grants from Eisai Pharmaceuticals, outside of the submitted work. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number 1026), and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}